Drug manufacturer Janssen Pharmaceuticals said last week it would pay refunds for overcharges on 340B drugs purchased in the second quarter of 2020, including top-selling psoriasis drug Stelara.
Janssen, part of Johnson & Johnson, said it owes or may owe refunds for charges above 340B ceiling prices on seven NDCs for drugs purchased between April 1 and June 30, 2020, according to a May 4 notice posted on the U.S. Health Resources and Services Administration website.
Drug manufacturer Janssen Pharmaceuticals said last week it would pay refunds for overcharges on 340B drugs purchased in the second quarter of 2020, including top-selling psoriasis drug Stelara. Janssen, part of Johnson & Johnson, said it owes or may owe […]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
